Johnson & Johnson wins EU nod for prostate cancer therapy (NYSE:JNJ)

Sundry Photography/iStock Editorial via Getty Images

Johnson & Johnson’s (NYSE:JNJ) Janssen unit announced Friday that a group of experts from the European Medicines Agency (EMA) recommended marketing authorization for its oral PARP inhibitor niraparib as a combination regimen for certain adults with

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *